Targeted delivery of flagellin by nebulization offers optimized respiratory immunity and defense against pneumococcal pneumonia
Antimicrobial Agents and Chemotherapy · 05.12.2024 · 68 (12)
DOI: 10.1128/aac.00866-24 ↗Kurz gefasst
Fachartikel in der Zeitschrift Antimicrobial Agents and Chemotherapy, erschienen am 05.12.2024. Verfasst von Mara Baldry und 12 weiteren Autor:innen. Beteiligte Einrichtung: Univ. Lille CNRS, Inserm, CHU Lille, Institut Pasteur de Lille, U1019 - UMR 9017 - CIIL - Center for Infection and Immunity of Lille, Lille, France. Hauptthemen laut MEDLINE: Flagellin, Pneumonia, Pneumococcal, Nebulizers and Vaporizers, Streptococcus pneumoniae. Die Arbeit wurde bisher 11-mal zitiert (Crossref) und nennt 55 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: EC | Horizon 2020 Framework Programme (H2020), Agence Nationale de la Recherche (ANR).
Abstract (Originalsprache)
Novel therapeutic strategies are urgently needed to combat pneumonia caused by Streptococcus pneumoniae strains resistant to standard-of-care antibiotics. Previous studies have shown that targeted stimulation of lung innate immune defenses through intranasal administration of the Toll-like receptor 5 agonist flagellin improves the treatment of pneumonia when combined with antibiotics. To promote translation to the clinic application, this study assessed the direct delivery of flagellin to the airways through nebulization using a vibrating mesh nebulizer in mice. Intranasal delivery achieved approximately 40% lung deposition of the administered flagellin dose, whereas nebulization yielded less than 1%. Despite these differences, nebulized flagellin induced transient activation of lung innate immunity characterized by cytokine/chemokine production and neutrophil infiltration into airways analogous to intranasal administration. Furthermore, inhalation by nebulization resulted in an accelerated resolution of systemic pro-inflammatory responses. Lastly, adjunct therapy combining nebulized flagellin and amoxicillin proved effective against antibiotic-resistant pneumococcal pneumonia in mice. We posit that flagellin aerosol therapy represents a safe and promising approach to address bacterial pneumonia within the context of antimicrobial resistance.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Univ. Lille CNRS, Inserm, CHU Lille, Institut Pasteur de Lille, U1019 - UMR 9017 - CIIL - Center for Infection and Immunity of Lille, Lille, France.
- INSERM, Respiratory Disease Research Centre, Tours, France.
- University of Tours, Tours, France.
- Univ. Lille CNRS, Inserm, CHU Lille, Institut Pasteur de Lille, US 41 - UAR 2014 - PLBS - Plateformes Lilloises de Biologie & Santé, Lille, France.
- Aerogen IDA Business Park, Dangan, Galway, Ireland.
ORCID-Profile: Mara Baldry, David Hot, Jean-Claude Sirard
Förderung
- EC | Horizon 2020 Framework Programme (H2020)
- Agence Nationale de la Recherche (ANR)
Zitieren
APA
Baldry, M., Costa, C., Zeroual, Y., Cayet, D., Pardessus, J., Soulard, D., Wallet, F., Beury, D., Hot, D., MacLoughlin, R., Heuzé-Vourc'h, N., Sirard, J. C., & Carnoy, C. (2024). Targeted delivery of flagellin by nebulization offers optimized respiratory immunity and defense against pneumococcal pneumonia. Antimicrobial Agents and Chemotherapy, 68(12). https://doi.org/10.1128/aac.00866-24
Vancouver
Baldry M, Costa C, Zeroual Y, Cayet D, Pardessus J, Soulard D, et al. Targeted delivery of flagellin by nebulization offers optimized respiratory immunity and defense against pneumococcal pneumonia. Antimicrobial Agents and Chemotherapy. 2024;68(12). doi:10.1128/aac.00866-24
BibTeX
@article{Baldry2024,
author = {Baldry, Mara and Costa, Charlotte and Zeroual, Yasmine and Cayet, Delphine and Pardessus, Jeoffrey and Soulard, Daphnée and Wallet, Frédéric and Beury, Delphine and Hot, David and MacLoughlin, Ronan and Heuzé-Vourc'h, Nathalie and Sirard, Jean-Claude and Carnoy, Christophe},
title = {Targeted delivery of flagellin by nebulization offers optimized respiratory immunity and defense against pneumococcal pneumonia},
journal = {Antimicrobial Agents and Chemotherapy},
year = {2024},
volume = {68},
number = {12},
doi = {10.1128/aac.00866-24}
}
EUVIMED